APNAT 60 MG

In the supplied oncology record, Apalutamide is associated with Prostate Cancer, particularly in the settings described as Non-metastatic castration-resistant prostate cancer; metastatic castration-sensitive/hormone-sensitive prostate cancer. Its pharmacological class is Androgen receptor inhibitor. The record specifically spans non-metastatic castration-resistant prostate cancer as well as metastatic hormone-sensitive disease, giving disease state a prominent role in how this agent is positioned. Directly inhibits androgen-receptor signaling by preventing receptor activation, nuclear translocation and transcription. Hormone-pathway suppression is the central therapeutic principle, with treatment selection shaped by the prostate cancer disease state or other hormone-sensitive context described in the indication. The treatment category is recorded as Hormonal / Endocrine Therapy; Androgen Receptor Inhibitor. Regimen examples include Apalutamide + ADT; apalutamide + ADT in metastatic hormone-sensitive disease. Rather than implying one universal use, these combinations show the range of contexts in which the medicine may be incorporated. The database places it within endocrine management, where the hormonal environment and disease state are important determinants of clinical use. Where the same agent is listed for more than one cancer, its role should not be assumed to be interchangeable between diseases. This summary is intentionally non-prescriptive and does not include individualized dosing. Current labeling and relevant disease guidance should be reviewed when the database is used for clinical decision support.